FDA Approves Subcutaneous Starting Dose for Leqembi Alzheimer's Treatment

The U.S. Food and Drug Administration (FDA) approved a weekly subcutaneous starting dose for Leqembi on July 13, 2026. This new method marks the first time patients can begin Alzheimer's treatment with at-home administration, aiming to improve accessibility and reduce the burden on patients and caregivers.

The subcutaneous approval is seen as a significant step towards more scalable care models needed as the field shifts from single-drug treatments to combination therapies. Laura Nisenbaum, PhD, Interim Chief Science Officer of the Alzheimer's Drug Discovery Foundation (ADDF), stated that making treatment more convenient and accessible is crucial for the future of Alzheimer's care, which is likely to be long-term and multi-drug. Dosing at home is essential for the sustainability of such regimens.

Clinical data presented concurrently showed that the weekly subcutaneous Leqembi performs similarly to the previously approved intravenous (IV) regimen, with a comparable safety profile. The subcutaneous injection takes approximately 15 seconds, a stark contrast to the hour-long IV infusions previously required at clinical sites. Patients previously underwent an 18-month IV initiation period before switching to subcutaneous maintenance.

Following Leqembi's progress, other companies like Eli Lilly are also testing subcutaneous formulations of their Alzheimer's drug candidates. The diversification of the Alzheimer's therapeutic pipeline across various targets necessitates flexible and scalable drug delivery methods. With nearly 75% of the current pipeline focusing on non-amyloid pathways, the ability to combine and personalize treatments will be critical. ADDF CEO Isobel Coleman described the approval as an inflection point, enabling more dynamic treatment strategies.